Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus

AIDS

Volumn 17, Issue 7, 2003, Pages

  Koelsch, Kersten K ^a   Smith, Davey M ^a   Little, Susan J ^a,b   Ignacio, Caroline C ^a   Macaranas, Theresa R ^a   Leigh Brown, Andrew J ^c   Petropoulos, Christos J ^d   Richman, Douglas D ^a,b   Wong, Joseph K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d MONOGRAM BIOSCIENCES   (United States)

Author keywords

Clade B; HIV 1; Superinfection; Virology

Indexed keywords

VIRUS RNA;

ANTIBIOTIC RESISTANCE; ARTICLE; CLADISTICS; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIMARY INFECTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURAL GENE; SUPERINFECTION; VIRUS LOAD; VIRUS STRAIN; WILD TYPE;

DNA, VIRAL; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SUPERINFECTION; VIRAL LOAD;

EID: 0037541489     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305020-00001     Document Type: Article

References (18)

1. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997, 3:205-211.
2. Goulder PJ, Rowland-Jones SL, McMichael AJ, Walker BD. Anti-HIV cellular immunity: recent advances towards vaccine design. AIDS 1999, 13 (Suppl. A):S121-S136.
3. Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, Johnson RP, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996, 156:2616-2623.
4. Malim MH, Emerman M. HIV-1 sequence variation: drift, shift, and attenuation. Cell 2001, 104:469-472.
5. Takehisa J, Zekeng L, Ido E, Yamaguchi-Kabata Y, Mboudjeka I, Harada Y, et al. Human immunodeficiency virus type 1 intergroup (M/O) recombination in Cameroon. J Virol 1999, 73:6810-6820.
6. Gao F, Robertson DL, Morrison SG, Hui H, Craig S, Decker J, et al. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J Virol 1996, 70:7013-7029.
7. Jetzt AE, Yu H, Klarmann GJ, Ron Y, Preston BD, Dougherty JP. High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol 2000, 74:1234-1240.
8. Kuwata T, Miyazaki Y, Igarashi T, Takehisa J, Hayami M. The rapid spread of recombinants during a natural in vitro infection with two human immunodeficiency virus type 1 strains. J Virol 1997, 71:7088-7091.
9. Jost S, Bernard MC, Kaiser L, Yerly S, Hirschel B, Samri A, et al. A patient with HIV-1 superinfection. N Engl J Med 2002, 347:731-736.
10. Ramos A, Hu DJ, Nguyen L, Phan KO, Vanichseni S, Promadej N, et al. Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J Virol 2002, 76:7444-7452.
11. Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, et al. HIV-1 superinfection despite broad CD8(+) T-cell responses containing replication of the primary virus. Nature 2002, 420:434-439.
12. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
13. Zhang L, Chung C, Hu BS, He T, Guo Y, Kim AJ, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 2000, 106:839-845.
14. Blackard JT, Cohen DE, Mayer KH. Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Infect Dis 2002, 34:1108-1114.
15. Otten RA, Ellenberger DL, Adams DR, Fridlund CA, Jackson E, Pieniazek D, Rayfield MA. Identification of a window period for susceptibility to dual infection with two distinct human immunodeficiency virus type 2 isolates in a Macaca nemestrina (pig-tailed macaque) model. J Infect Dis 1999, 180:673-684.
16. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999, 282:1135-1141.
17. Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999, 282:1142-1149.
18. Daar ES, Frost SD, Wong JK, Hellmann NS, Wrin T, Petropoulos CJ, et al. Mixed infection with multidrug resistant MDR and wild type HIV strains in primary HIV infection (PHI): early viral rebound suggests loss of immune control. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 24-28 February 2002 [Abstract 96].